<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03076580</url>
  </required_header>
  <id_info>
    <org_study_id>BeijingIHLBVD2016031</org_study_id>
    <nct_id>NCT03076580</nct_id>
  </id_info>
  <brief_title>An Integrative-&quot;Omics&quot; Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China</brief_title>
  <acronym>AOCC</acronym>
  <official_title>An Integrative-omics Study to Identify New Biomarkers of Cardiomyopathy Patients in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Institute of Heart, Lung and Blood Vessel Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Institute of Heart, Lung and Blood Vessel Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-omics research of Chinese cardiomyopathies patients, aiming to determine
      genetic risk factor and serial biomarkers of cardiomyopathies in diagnosis and prognosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Identification of novel biomarkers is needed to improve the diagnosis and prognosis of
      cardiomyopathy. Also,the marked variation of genes which is still unclear, may influence
      clinical outcomes is determined in part by genetic heterogeneity of the systemic response to
      pathological process.

      Specific aim:

        1. Proteomics, microRNA-seq and metabolomics will be to determine the correlation of
           echocardiographic parameters of systolic and diastolic functional entry with circulating
           molecules

        2. Genomics will be to determine the association of clinical outcome
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to determine whether variation in genetic background or differentially expressed molecules influences clinical outcomes in cardiomyopathy.</measure>
    <time_frame>Five year</time_frame>
    <description>The primary objective of this study is to determine whether variation in genetic background or molecules influences clinical outcomes in cardiomyopathy. Differentially expressed molecules are reported in multi-omics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Age for each participant</measure>
    <time_frame>These data is collected from the cases' medical record in an average of 1 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gender for each participant</measure>
    <time_frame>These data is collected from the cases' medical record in an average of 1 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height for each participant</measure>
    <time_frame>These data is collected from the cases' medical record in an average of 1 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight for each participant</measure>
    <time_frame>These data is collected from the cases' medical record in an average of 1 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Past medical history for each participant including disease history, surgical history, and family</measure>
    <time_frame>These data is collected from the cases' medical record in an average of 1 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life style for each participant including smoking history and drinking, specify how many years</measure>
    <time_frame>These data is collected from the cases' medical record in an average of 1 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood lipids(LDL,HDL,VLDL)</measure>
    <time_frame>These data is collected from the cases' medical record in an average of 1 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatine</measure>
    <time_frame>These data is collected from the cases' medical record in an average of 1 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urea</measure>
    <time_frame>These data is collected from the cases' medical record in an average of 1 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood glucose</measure>
    <time_frame>These data is collected from the cases' medical record in an average of 1 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>These data is collected from the cases' medical record in an average of 1 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP</measure>
    <time_frame>These data is collected from the cases' medical record in an average of 1 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>One year/Three year/Five year</time_frame>
    <description>The data is collected during follow-up visit at 1/3/5 years after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization</measure>
    <time_frame>One year/Three year/Five year</time_frame>
    <description>Patients are hospitalized due to heart failure with decreasing left ventricular ejection fraction or worsen symptoms. The data is collected during follow-up visit at 1/3/5 years after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart transplantation</measure>
    <time_frame>One year/Three year/Five year</time_frame>
    <description>Patients are underwent heart transplantation due to &quot;pump failure of heart&quot;.The data is collected during follow-up visit at 1/3 years after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malignant arrythmia</measure>
    <time_frame>One year/Three year/Five year</time_frame>
    <description>Ventricular flutter and fibrillation, atrioventricular block,atrial fibrillation or other cardiac arrhythmia leads to syncope or should be Implantable Cardioverter-Defibrillator (ICD) implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening heart failure</measure>
    <time_frame>One year/Three year/Five year</time_frame>
    <description>Worsen heart failure is defined as decreased ejection fraction(left ventricular ejection fraction decreased over 10%), left ventricular ejection fraction &lt;45% and enlarged heart size measured by echocardiography and changing level of New York Heart Association (NYHA) Functional Classification.And patients who undergo left ventricular assist device (LVAD) will also be included.The data is collected during follow-up visit at 3/6/9/12/36/60 months after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RNA/micro RNA/long-noncoding RNA-sequencing data</measure>
    <time_frame>The data is collected from lab in an average of 6 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomics on Liquid Chromatograph Mass Spectrometer/Mass Spectrometer of plasma sample</measure>
    <time_frame>The data is collected from lab in an average of 6 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exon sequencing data</measure>
    <time_frame>The data is collected from lab in an average of 6 month after the sample recruiting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Result of echocardiography-Ejection Fraction</measure>
    <time_frame>Three year</time_frame>
    <description>The whole results of echocardiography report will be recorded. The indicate can reflect cardiac contraction function and be used for discriminating heart failure or non-heart failure as a main factor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Result of echocardiography-Left Ventricular End Diastolic Diameter</measure>
    <time_frame>Three year</time_frame>
    <description>The whole results of echocardiography report will be recorded. The indicate can reflect the size of heart and be used for determination of heart enlargement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Result of echocardiography-E/A Ratio</measure>
    <time_frame>Three year</time_frame>
    <description>The whole results of echocardiography report will be recorded. The indicate can reflect diastolic function.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <condition>Arrhythmogenic Right Ventricular Cardiomyopathy</condition>
  <condition>Left Ventricular Non-compaction</condition>
  <condition>Restrictive Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>cardiomyopathy</arm_group_label>
    <description>Patients are diagnosed as cardiomyopathy by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>disease control</arm_group_label>
    <description>Patients have similar symptoms with cardiomyopathy patients, and are further excluded by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control</arm_group_label>
    <description>Healthy subjects are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      If a blood specimen is obtained, it will be separated and stored at -80 â„ƒ as plasma, viable
      cells, and extracted DNA. If a saliva specimen is obtained, it is stored for DNA. If a tissue
      specimen is obtained, it will be cut into small pieces and stored at liquid nitrogen.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A diagnosis of cardiomyopaty is adjudicated by three cardiologists,according to current
        guidelines when there was clinical evidence of cardiomyopathy together with clinical
        symptoms of heart failure or echocardiography or imaging evidence.

        Patients have smiliar symptoms and are suspected as cardiomyopathy and further excluded by
        imaging examnation.

        age- and gender- mathced healthy controls are also recuitted in the hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who was diagnosed as cardiomyopathy by medical history, clinical symptoms,
             laboratory tests including ECG, echocardiography.

          2. Subject understands study requirements aand agrees to sign an informed consent form
             prior to any study procedures.

        Exclusion Criteria:

          1. Endocrine disease known to cause heart muscle disease (including infants of diabetic
             mothers)

          2. History of rheumatic fever

          3. Toxic exposures known to cause heart muscle disease (anthracyclines, mediastinal
             radiation, iron overload or heavy metal exposure)

          4. HIV infection or born to an HIV positive mother

          5. Kawasaki disease

          6. Immunologic disease

          7. Uremia, active or chronic

          8. Abnormal ventricular size or function that can be attributed to intense 9.physical
             training or chronic anemia

        10.Chronic arrhythmia, unless there are studies documenting inclusion criteria prior to the
        onset of arrhythmia (except a patient with chronic arrhythmia, subsequently ablated, whose
        cardiomyopathy persists after two months is not to be excluded) 11.Malignancy 12.Pulmonary
        parenchymal or vascular disease (e.g., cystic fibrosis, cor pulmonale, or pulmonary
        hypertension) 13.Ischemic coronary vascular disease 14.Association with drugs (e.g., growth
        hormone, corticosteroids, cocaine) or other diseases known to cause hypertrophy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Du, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Anzhen Hospital affiliated to Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Du, PhD</last_name>
    <email>jiedubj@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yulin Li, PhD</last_name>
    <email>lyllyl_1111@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Institute of heart, lung and blood vessel diseases</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Du</last_name>
      <email>jiedubj@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yulin Li</last_name>
      <email>lyllyl_1111@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yang Li, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongzhao You, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Institute of heart, lung and blood vessel diseases</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Du</last_name>
      <email>jiedubj@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yulin Li</last_name>
      <email>lyllyl_1111@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yang Li, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongzhao You, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongqiang Lai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shijie You</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
    <mesh_term>Cardiomyopathy, Restrictive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

